Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
Open Access
- 1 August 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 6 (8), 627-635
- https://doi.org/10.1016/S2213-2600(18)30181-4
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosisBMC Pulmonary Medicine, 2014
- Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Autotaxin--an LPA producing enzyme with diverse functionsThe Journal of Biochemistry, 2010
- The SF-36 and SGRQ: Validity and first look at minimum important differences in IPFRespiratory Medicine, 2010
- Incidence and Prevalence of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory QuestionnaireAmerican Review of Respiratory Disease, 1992